We provide integrated product development services to enable our partners to bring vaccines and biopharmaceutical products to market.
With over 20 years of experience, we have significant expertise in EU-licensed GMP manufacturing, technology transfer, and project management. We integrate our services into our partners’ programs, from preclinical through clinical development, and to support commercial manufacturing.
Our services have helped our partners bring to market products which include hepatitis B vaccines, combination vaccines, human insulin, human IFNα-2a, and hirudin.
Our integrated product development services include:
We license our proprietary technologies to our partners for worldwide use. One of our leading platforms is our proprietary Hansenula polymorpha yeast expression technology, which currently is used for the commercial manufacturing of several recombinant biopharmaceutical products and vaccines.
In addition, we offer expert immunology services and are equipped to provide GLP testing of preclinical and clinical samples. We have an OECD-GLP Certificate that includes serological testing for characterization of immune responses, analytical testing of biological materials, and cell bank characterization.
For more details, please refer to the following fact sheets:
GMP Product Development Services.
Cell Banking and Strain Characterization Services
For additional information, please contact us at bd(at)rheinbiotech.de
Rhein Biotech GmbH
Dynavax Europe
Eichsfelder Strasse 11
D-40595 Düsseldorf
Phone: +49 (0)211 7 58 45 0
Fax: +49 (0)211 7 58 45 130
E-Mail: info(at)rheinbiotech.de
![]() |